4//SEC Filing
Shabbir Anik 4
Accession 0001209191-23-016739
CIK 0001382101other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:24 PM ET
Size
15.4 KB
Accession
0001209191-23-016739
Insider Transaction Report
Form 4
Shabbir Anik
Chief Technical Ops. Officer
Transactions
- Exercise/Conversion
Common Stock
2023-03-03+7,875→ 38,299 total - Exercise/Conversion
Common Stock
2023-03-03+8,750→ 47,049 total - Tax Payment
Common Stock
2023-03-03$5.79/sh−6,222$36,025→ 40,827 total - Award
Restricted Stock Unit (RSU)
2023-03-03+40,000→ 40,000 totalExp: 2025-03-01→ Common Stock (40,000 underlying) - Exercise/Conversion
Restricted Stock Unit (RSU)
2023-03-03−7,875→ 23,625 totalExp: 2026-03-04→ Common Stock (7,875 underlying) - Exercise/Conversion
Restricted Stock Unit (RSU)
2023-03-03−8,750→ 17,500 totalExp: 2025-03-05→ Common Stock (8,750 underlying)
Footnotes (5)
- [F1]Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
- [F2]Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
- [F3]The RSUs vest as to 1/2 of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
- [F4]The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
- [F5]The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.
Documents
Issuer
SUTRO BIOPHARMA, INC.
CIK 0001382101
Entity typeother
Related Parties
1- filerCIK 0001751728
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:24 PM ET
- Size
- 15.4 KB